Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary histopathologic changes associated with melphalan therapy.

R Taetle, P S Dickman, P S Feldman

    Cancer
    |September 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Graph models of oncogenesis with an application to melanoma.

    Journal of theoretical biology·2001
    Same author

    High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
    Same author

    The frozen section yesterday and today: pediatric solid tumors--crucial issues.

    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·2001
    Same author

    Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases.

    Cancer genetics and cytogenetics·2000
    Same author

    Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis.

    Genes, chromosomes & cancer·2000
    Same author

    Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.

    Cancer chemotherapy and pharmacology·1999
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Melphalan, a chemotherapy drug, can cause severe lung damage, including pulmonary fibrosis and atypical epithelial proliferation (AEP). This finding highlights the need for careful monitoring in multiple myeloma patients undergoing melphalan treatment.

    Area of Science:

    • Pulmonary Medicine
    • Oncology
    • Toxicology

    Background:

    • Multiple myeloma is a cancer of plasma cells.
    • Melphalan is a chemotherapy agent used in multiple myeloma treatment.

    Observation:

    • A fatal case of pulmonary fibrosis and atypical epithelial proliferation (AEP) was observed in a patient with multiple myeloma treated with melphalan.
    • A review of autopsied patients revealed similar pulmonary changes in others treated with melphalan.

    Findings:

    • Melphalan treatment is associated with severe fibrotic pulmonary reactions.
    • Atypical epithelial proliferation (AEP) can occur in the lungs secondary to melphalan exposure.
    • No such pulmonary changes were noted in control groups not treated with cytotoxic agents.

    Related Experiment Videos

    Implications:

    • Melphalan should be recognized as a potential cause of drug-induced lung injury.
    • Clinicians should consider pulmonary toxicity in patients with multiple myeloma receiving melphalan.
    • Further research is warranted to understand the mechanisms of melphalan-induced pulmonary fibrosis and AEP.